最新ニュース LogicMark (NASDAQ:LGMK) 株価情報

LogicMark

LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.

LogicMark Inc

News

ZAPP

Zapp EV Expands Into Ireland With Appointment Of First Authorised Reseller In Dublin

Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) is looking for Q2 Adj EPS of $0.55-$0.59 vs $0.56 analyst estimate. sees sales of $3.850 billion vs $3.82 billion analyst estimate.

Guidance

Corning Sees Q2 Adj EPS $0.55-$0.59 vs $0.56 Est; Sees Core Sales $3.850B vs $3.82B Est

Rosenblatt analyst Barton Crockett initiates coverage on Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy rating and announces Price Target of $18.

Price Target

Initiation

Analyst Ratings

MGNI

Rosenblatt Initiates Coverage On Magnite with Buy Rating, Announces Price Target of $18

Outlook
"In the first quarter we saw booking strength from January deteriorate into February and worsen into March," said Marty St. George, JetBlue's president. "We expect softened demand for off-peak travel to continue into the second quarter, where the booking curve is more exposed to macro uncertainty and deteriorating consumer confidence. That said, we are committed to our JetForward plan and are encouraged by the resiliency of premium, international, and loyalty revenues - core components of our long-term strategy."
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Second Quarter and Full Year 2025 Outlook</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Estimated 2Q 2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Estimated FY 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Available Seat Miles ("ASMs") Year-Over-Year</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(3.5%) - (0.5%)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1">RASM Year-Over-Year</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(7.5%) - (3.5%)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CASM Ex-Fuel (1), (2) Year-Over-Year</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">6.5% - 8.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Fuel Price per Gallon (3), (4)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.25 - $2.40</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~$600 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~$400 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~$1.3 billion</td>
</tr>
</tbody>
</table>
</figure>

Earnings

General

JBLU

JetBlue Expects Q2 2025 Available Seat Miles Year-Over-Year Decline Of (3.5%)-(0.5%)

<a href="https://www.globenewswire.com/Tracker?data=k_AP_7XwuO_5EvdiadgYRFP1KPG3qzFhiqX_4zqt3CDb9xzai6sghaCP31YDkTwxUUtoLxQbVADKnGnRFMYl4ACebhgINwmMpoD72kF-kCs=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004.
The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition (<a href="https://www.globenewswire.com/Tracker?data=egYAj5B3mYmpOUcK43ywwcGpLB2F9iZ-eYuWoa7kAJ2DEbDIoZyJn5QkulzNtWo810-AKcngoFR72fmYBaqr563TQG-3O60UH-79X1hJdMLIKaG0LK8wjAx9eDccTjkx">NCT06299839</a>).
 &nbsp;

KTTA

Pasithea Therapeutics Completes Enrollment And Initial Dosing Of Three Subjects In Cohort 6 With 30 Mg Capsules Of PAS-004

Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.51 by 5.88 percent. This is a 42.11 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $3.68 billion which beat the analyst consensus estimate of $3.64 billion by 0.98 percent. This is a 12.92 percent increase over sales of $3.26 billion the same period last year.

Earnings Beats

Corning Q1 Adj. EPS $0.54 Beats $0.51 Estimate, Sales $3.68B Beat $3.64B Estimate

WIIM

PYPL

PayPal shares are trading lower following a Q1 revenue miss.

LCII

LCI Industries Acquires Freedman Seating, Expanding Lippert's Reach In Transportation Vehicle Market

LGI Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) reported quarterly earnings of $0.43 per share which missed the analyst consensus estimate of $0.63 by 31.75 percent. This is a 40.28 percent decrease over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $351.42 million which missed the analyst consensus estimate of $366.45 million by 4.10 percent. This is a 10.09 percent decrease over sales of $390.85 million the same period last year.

Earnings Misses

LGIH

LGI Homes Q1 Adj. EPS $0.43 Misses $0.63 Estimate, Sales $351.42M Miss $366.45M Estimate

Financial Guidance 2025 Guidance: PayPal is maintaining full year guidance due to uncertainty in the global macro environment despite a strong start to the year.&nbsp;

PayPal Holdings Affirms FY2025 Adj EPS Guidance $4.95-$5.10 vs $5.01 Est.; Sees Q2 Adj EPS $1.29-$1.31 vs $1.21 Est.; Says Guidance Unchanged Amid Global Economic Uncertainty, Despite A Strong Start To The Year

Rosenblatt analyst Barton Crockett maintains Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Buy and maintains $20 price target.

Rosenblatt Maintains Buy on Viant Technology, Maintains $20 Price Target

Biotech

TVTX

Travere Therapeutics And CSL Vifor Announce Standard European Commission Approval Of FILSPARI For IgA Nephropathy

<a href="https://www.globenewswire.com/Tracker?data=z4BvZbQWX7PceEc36Af6HN5ny_R9Tyu4VqPcLv8rjHvviJ4c1Ea5AFWM6LImHc3G-yesisVeVvNbDYBRkhLP3vlRHrtKAK4cG4Igju5ZFgonjqBw-e3MG-E6R8il5Jba">Cullinan Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the Company is initiating a study of CLN-978 in patients with Sjögren's disease (SjD) in the U.S. The Company previously received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) Application clearance to study the CD19 T cell engager in patients with moderate to severe systemic lupus erythematosus (SLE) and European Medicines Agency (EMA) approval to study CLN-978 in active, difficult-to-treat rheumatoid arthritis.
The trial will enroll patients with active, moderate to severe Sjögren's disease who fulfill the 2016 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria and are positive for anti-SSA/RO antibodies and/or rheumatoid factor. The dose escalation scheme will be similar to the SLE study. The primary objective of the study is to evaluate the safety and tolerability of CLN-978 in patients with SjD. Secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity. The Company expects to initiate the study this quarter.

CGEM

Cullinan Launches Study for Treatment Aimed at Sjögren's Patients

Matthew Harbaugh named Chief Financial Officer; management team fully staffed ahead of spin-off
Change to future Board Chair announced
WILMINGTON, Del., April 29, 2025 /PRNewswire/ --&nbsp;DuPont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) today announced Qnity Electronics, Inc. ("Qnity") as the name of the planned independent Electronics public company that will be created through the intended spin-off of its Electronics business&#x2A;. As a pure-play electronics materials company, Qnity will be one of the largest and broadest solutions providers to the semiconductor and electronics industries enabling advanced computing, smart technologies and connectivity.
DuPont also announced that Matthew Harbaugh will join the company effective May 1, 2025, and will be the Chief Financial Officer of Qnity.
 &nbsp;

DuPont Unveils Qnity Electronics As Planned Independent Public Company In Electronics Spin-Off; Names Matthew Harbaugh CFO Of Qnity, Effective May 1, 2025

Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) raises FY2025 Adj EPS guidance from $1.59-$1.69 to $1.61-$1.70 vs $1.46 analyst estimate. Raises FY2025 sales outlook from $5.30 billion-$5.50 billion to $5.40 billion-$5.60 billion vs $5.43 billion estimate.

OPCH

Option Care Health Raises FY2025 Adj EPS Guidance from $1.59-$1.69 to $1.61-$1.70 vs $1.46 Est; Raises FY2025 Sales Guidance from $5.30B-$5.50B to $5.40B-$5.60B vs $5.43B Est

Dividends

First Commonwealth Financial Declared Quarterly Dividend Of $0.135 Per Share, Which Represents A 3.9% Increase From The Previous Quarter. The Cash Dividend Is Payable On May 23 To Shareholders Of Record As Of May 9

AEVA

Aeva Unveils Eve 1D: First FMCW-Based Laser Displacement Sensor Targeting $4B Industrial Automation Market

NWTG

Newton Golf Company Announces The Launch Of Its Newest Shaft Family, Newton Fast Motion, Now Available For Purchase At A Suggested Retail Price Of $325

The two new interval funds employ a thoughtful and deliberate approach, designed from the ground up to deliver blended public-private markets exposure with a risk, return and liquidity profile driven by input from financial advisors and a focus on investor needs and outcomes. Defining features include:
<ul>
<li>Public credit and private credit exposures combined into a single, holistic solution: over time, and subject to market conditions, each fund will seek to allocate approximately 60% of net assets to public fixed income and 40% to private credit consisting of direct lending and asset-based finance investments.</li>
<li>Improved liquidity relative to standalone alternatives: quarterly repurchase offers up to 10% of the fund's outstanding shares at net asset value (NAV). Most interval funds offer 5% quarterly liquidity1.</li>
<li>Highly competitive total expense ratios2:
<ul>
<li>Capital Group KKR Core Plus+ at 84 basis points</li>
<li>Capital Group KKR Multi-Sector+ at 89 basis points</li>
</ul>
</li>
<li>Low investment minimum of $1,000 for all share classes.</li>
</ul>

KKR, Capital Group To Expand Exclusive Strategic Partnership, Launch 2 Public-Private Investment Solutions

Needham analyst Ryan Koontz assumes F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Buy rating and announces Price Target of $320.

FFIV

Needham Assumes F5 at Buy, Announces Price Target of $320

LogicMark Launches Critical New Device To Save Lives

Health Care

Press Releases

LogicMark Secures Approval to Provide Essential Safety Devices Through Medicaid Waiver Programs to Seniors in Key States

Empowering Independence: How LogicMark Supports Aging Adults At Home And Beyond

AI In Healthcare Matters: How LogicMark Leverages AI In Its Advanced Monitoring Devices

LogicMark Launches Next Generation of Guardian Alert 911 Plus Technology

LogicMark, Inc. Announces Pricing of $14.4 Million Public Offering and Plan to Hold Special Stockholder Meeting on March 24, 2025

Financing

LogicMark, Inc. Announces Closing of $14.4 Million Public Offering

LogicMark Secures Approval to Deliver New Medical Alert with Cell Phone Tech to Veterans and Seniors Through U.S. General Services Administration

Gold Terra (TSX.V: YGT) Secures C$4.4M Funding, Drilling Progresses in Yellowknife – More Stocks Under 10 Cents Inside

Management

LogicMark, Inc. Unveils New Board Committee Leadership Structure to Align with Strategic Goals

CBDW

CSE:SKUR

LGMK

STSS

SWISF

TSXV:YGT

YGTFF

Bluejay Diagnostics

GlucoTrack

HeartSciences

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

Know Labs

NanoVibronix

ENDRA Life Sciences

Nuwellis

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems

Venus Concept

Catheter Precision

Screenshot 2025-03-28 at 8.49.42 PM

Movers & Shakers

Interview

LogicMark Strives To Drive Growth In Personal Safety Through Innovation

Screenshot 2025-02-27 at 9.37.47 PM

Emerging Markets

LogicMark Is Leveraging AI To Transform Personal Safety

Screenshot 2025-02-25 at 11.34.41 PM

Medical Devices Designed For Every Possibility

Screenshot 2025-02-07 at 6.23.18 PM

Screenshot 2025-02-05 at 6.26.42 PM

Markets

Screenshot 2024-12-23 at 8.42.42 PM

Screenshot 2024-12-16 at 6.46.28 PM

From Seniors To Sorority Sisters: How LogicMark&#39;s Aster App Expands Personal Safety Across Generations

Screenshot 2024-11-19 at 6.42.59 PM

LogicMark Offers Safety Technology for Free To American Veterans Nationwide

Screenshot 2024-11-06 at 7.22.45 PM

Unintentional Falls Number 1 Cause Of Death For Americans Over 65, 40% Of Americans Scared Of Walking Alone At Night – LogicMark Offers Solutions

Screenshot 2024-10-18 at 5.31.39 PM

How LogicMark Is Helping Make Personal Safety Smarter

Comments

LogicMark

ニュース

最新ニュース LogicMark (NASDAQ:LGMK) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル